AAIC 2025 Abstract·9 JanPlasma proteomic analysis of a biomarker‐defined subpopulation in the SHINE Ph2 trial to identify molecular correlates to the favorable decrease in the neuroinflammatory marker GFAP with zervimesine in Alzheimer's disease participantsTrial in peopleInterventionsPaper